Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (154)
  • Open Access

    ARTICLE

    Prolonged Survival in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressed Metastatic Breast Cancer after Targeted Therapy is Dominantly Contributed by Luminal-Human Epidermal Growth Factor Receptor-2 Population

    Keiichi Kontani1,*, Kana Kuraishi1, Shin-ichiro Hashimoto1, Shoko Norimura2, Nozomi Hashimoto1, Masahiro Ohtani3, Naomi Fujiwara-Honjo4, Manabu Date5, Koji Teramoto6, Hiroyasu Yokomise1

    Oncologie, Vol.23, No.2, pp. 229-239, 2021, DOI:10.32604/Oncologie.2021.016277

    Abstract The prognosis of patients with human epidermal growth factor receptor-2 (HER2)-overexpressed metastatic breast cancer (MBC) has improved drastically following the development of anti-HER2 therapies. We question what factors are involved in the improved outcome by the treatment. One hundred and two MBC patients who received chemotherapy were classified into groups according to breast cancer subtype: luminal/HER2-negative (n = 50), HER2 (n = 26), and triple-negative subtypes (n = 26). Clinicopathologic features and clinical outcomes of the groups were compared. Disease-free intervals in the triple-negative group were significantly shorter than those in the other two groups. Age, tumor grade, the number… More >

  • Open Access

    ARTICLE

    Alteration of Ornithine Metabolic Pathway in Colon Cancer and Multivariate Data Modelling for Cancer Diagnosis

    Xin Hu1,2,#, Fangyu Jing3,#, Qingjun Wang1,4, Linyang Shi1, Yunfeng Cao4,5, Zhitu Zhu1,4,*

    Oncologie, Vol.23, No.2, pp. 203-217, 2021, DOI:10.32604/Oncologie.2021.016155

    Abstract It is noteworthy that colon cancer is the fourth place in new cases and the fifth in mortalities according to global cancer statistics 2018. Tumorigenesis displays specific correlation with metabolic alterations. A variety of metabolites, including ornithine (Orn), are related to colon cancer according to sources of disease metabolic information retrieval in human metabolome database. The metabolic regulation of Orn pathway is a key link in the survival of cancer cells. In this study, the plasma Orn levels in colon cancer patients and healthy participants were measured by liquid chromatography tandem mass spectrometry, and the metabolic disturbances of Orn in… More >

  • Open Access

    ARTICLE

    Growth and Invasion of 3D Spheroid Tumor of HeLa and CasKi Cervical Cancer Cells

    Kalaivani Muniandy1, Zuhaida Asra Ahmad1,4, Sylvia Annabel Dass1, Shaharum Shamsuddin2, Nethia Mohana Kumaran3, Venugopal Balakrishnan1,*

    Oncologie, Vol.23, No.2, pp. 279-291, 2021, DOI:10.32604/Oncologie.2021.015969

    Abstract Spheroids are generally self-assembled cells with the ability to generate their extracellular matrix, including the complex cell-matrix and the cell-cell interactions that resemble the functional characteristics of the corresponding tissue in vivo. The study aimed to develop a three-dimensional (3D) spheroid system for the cervical cancer cell lines, HeLa (HPV18), CaSki (HPV16), SiHa (HPV16), C33A (non-HPV), HT3 (non-HPV) as well as to identify its biological activity in the extracellular form. For the formation of the cervical cancer spheroids, the liquid overlay approach was applied, followed by embedding to the bovine collagen I matrix. Spheroid formation using the liquid overlay approach… More >

  • Open Access

    ARTICLE

    Tolerance and Efficacy of Regorafenib according to UGT Pharmacogenetical Status in the Treatment of Metastatic Refractory Colorectal Cancer

    Pierre-Guillaume Poureau1,2,*, Estelle Dhamelincourt2, Jessica Nguyen2, Hélène Babey2, Emmanuelle Renaud2, Margaux Geier2, Michèle Boisdron-Celle3, Jean-Philippe Metges2

    Oncologie, Vol.23, No.2, pp. 195-202, 2021, DOI:10.32604/Oncologie.2021.015929

    Abstract Introduction: Regorafenib is a multi tyrosin-kinase inhibitor prescribed in metastatic refractory colorectal cancer treatment. Its toxicity is significant but inconstant. The metabolism of regorafenib includes oxydation via cytochrome P3A4, then glucuroconjugation. A pharmacogenetical approach of mutational status of Uridine-Diphospho-Glucuronosyltransfersase (UDP-glucuronosyl-transferase, UGT) could be a strategy to optimise the use of regorafenib. Patients and Method: This is a restrospective, unicentric study. All adult patients treated with regorafenib for a metastatic colorectal cancer in our center between 2013 and 2017 were analysed. UGT1A1 polypmorphism was previously researched in the laboratory after written informed consent. Results: Thirty-five patients received regorafenib during the study… More >

  • Open Access

    REVIEW

    MicroRNA in HCC: Biomarkers and Therapeutic Targets

    Zheng Wang1, Yongxia He1, Yuwei Song1, Yue Wang2, Feng Chen3,*

    Oncologie, Vol.23, No.2, pp. 177-184, 2021, DOI:10.32604/Oncologie.2021.014773

    Abstract Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality. At present, diagnostic methods such as imaging observation, serum testing and tissue biopsy, as well as treatment methods such as surgical resection, radiotherapy, and chemotherapy have certain limitations in clinical interventions for HCC due to the complex pathogenesis and drug resistance of liver cancer, which seriously affect the survival and prognosis of patients. As a large-scale cytokine, microRNA (miRNA) plays an important role in regulating various life activities of cells. Extensive evidence proved that certain miRNAs are specifically expressed in the tissues and blood of HCC patients, and… More >

  • Open Access

    ARTICLE

    Accès au premier traitement : apport d’un centre de prise en charge rapide
    Access to First Treatment: Contribution of a Quick Care Centre

    E. du Rouchet, C. Dendoncker

    Oncologie, Vol.21, No.2, pp. 125-134, 2019, DOI:10.3166/onco-2019-0042

    Abstract For a patient suffering from breast cancer, access to the initial treatment includes several steps like confirmation of an anatomopathological diagnosis, proposition and establishment of an individualized treatment plan, pretreatment assessments, and access to the technical platform. The accumulated duration of these intervals plays a role in the prognosis in the early stages of the disease. In addition, it is important to manage all the uncertainties, both diagnostic and prognostic, which will inevitably upset the patient’s psychological balance. Supported by literature, recommendations and more than 20 years of experience in a multidisciplinary centre, the authors propose the organization of an… More >

  • Open Access

    ARTICLE

    Classifications des tumeurs neuroendocrines gastroentéropancréatiques : ce qui change*
    Classifications of gastro-entero-pancreatic neuroendocrine tumors: what has changed ?

    J.-Y. Scoazec

    Oncologie, Vol.21, No.2, pp. 119-124, 2019, DOI:10.3166/onco-2019-0052

    Abstract The WHO classification of the tumors of endocrine organs, published in July 2017 and that of digestive tumors, released in July 2019, have introduced significant changes in the classification of gastro-entero-pancreatic neuroendocrine tumors (NETs), which was unchanged since 2010. The main change is a new category of well-differentiated neoplasms, NET G3, in addition to the two previous categories NET G1 and NET G2. The other changes are: 1) the cut-off in Ki-67 index between NET G1 and G2, now set at 3%, 2) the term used for mixed tumors: MiNEN (mixed neuroendocrine-non neuroendocrine neoplasm) instead of MANEC (mixed adenoneuroendocrine carcinoma).… More >

  • Open Access

    ARTICLE

    Épidémiologie des tumeurs neuroendocrines intestinales *
    Epidemiology of Neuroendrocine Intestinal Tumours

    C. Lepage

    Oncologie, Vol.21, No.2, pp. 113-117, 2019, DOI:10.3166/onco-2019-0051

    Abstract Little is known about the epidemiology of digestive neuroendocrine tumours (NETs). NETs remain a rare cancer, representing 1% of all digestive cancers. In France, incidence rates are estimated to around 1.1/100,000 inhabitants in males and 0.9/100,000 in females. The incidence rates got increased over time, with probably more than 1,000 new cases per year in France. Because of their relatively good prognosis, NETs are the second more prevalent digestive cancer after colorectal cancer. Most digestive NETs are well-differentiated (WDNETs); poorly differentiated neuroendocrine carcinomas (PDNEC) account for less than 20% of the cases in most of the series. Among bowel-NETs, the… More >

  • Open Access

    ARTICLE

    Diagnostic des phéochromocytomes et paragangliomes *
    Diagnosis of Pheochromocytomas and Paragangliomas

    F. Castinetti, A. Barlier, F. Sebag, D. Taieb

    Oncologie, Vol.21, No.2, pp. 105-111, 2019, DOI:10.3166/onco-2019-0050

    Abstract Pheochromocytoma and paraganglioma are tumors leading to increased morbidity and mortality. Over the last 20 years, several major advances allowed a better characterization of these tumors, either from an imaging or from a genetic viewpoint. This is especially the case for the hereditary characteristics of these tumors, as roughly 20 new genes have been identified. This is why the initial steps of the management of a pheochromocytoma and/or a paraganglioma now require a dedicated tertiary referral center. The aim of this review is to depict the diagnostic steps of these tumors, so as to allow the clinician to determine the… More >

  • Open Access

    ARTICLE

    Traitement des néoplasmes neuroendocrines digestifs*
    Neuroendocrine neoplasms of the digestive system

    E. Baudin, J. Hadoux, T. de Baere, A. Berdelou, L. Tselikas, C. Caramella, M. Terroir, V. Boige, D. Goere, M. Faron, F. Deschamps, P. Burtin, S. Leboulleux, D. Malka, J.-Y. Scoazec, M. Ducreux

    Oncologie, Vol.21, No.2, pp. 97-103, 2019, DOI:10.3166/onco-2019-0049

    Abstract This article has no abstract. More >

Displaying 91-100 on page 10 of 154. Per Page